Publications dans lesquelles il/elle collabore avec Jordi Carratalà Fernández (22)

2023

  1. Cloxacillin plus fosfomycin versus cloxacillin alone for methicillin-susceptible Staphylococcus aureus bacteremia: a randomized trial

    Nature Medicine, Vol. 29, Núm. 10, pp. 2518-2525

  2. Contemporary use of cefazolin for MSSA infective endocarditis: analysis of a national prospective cohort

    International Journal of Infectious Diseases, Vol. 137, pp. 134-143

  3. Efficacy of ceftazidime-avibactam in solid organ transplant recipients with bloodstream infections caused by carbapenemase-producing Klebsiella pneumoniae

    American Journal of Transplantation, Vol. 23, Núm. 7, pp. 1022-1034

  4. Impact of Intermediate Susceptibility to Penicillin on Antimicrobial Treatment and Outcomes of Endocarditis Caused by Viridans and Gallolyticus Group Streptococci

    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, Vol. 77, Núm. 9, pp. 1273-1281

  5. Impact of SARS-CoV-2 RNAemia and other risk factors on long-COVID: A prospective observational multicentre cohort study

    Journal of Infection

  6. Isavuconazole for the Treatment of Invasive Mold Disease in Solid Organ Transplant Recipients: A Multicenter Study on Efficacy and Safety in Real-life Clinical Practice

    Transplantation, Vol. 107, Núm. 3, pp. 762-773

2022

  1. Outpatient Parenteral Antibiotic Treatment vs Hospitalization for Infective Endocarditis: Validation of the OPAT-GAMES Criteria

    Open Forum Infectious Diseases, Vol. 9, Núm. 9

2021

  1. Clinical Features and Outcomes of Streptococcus anginosus Group Infective Endocarditis: A Multicenter Matched Cohort Study

    Open Forum Infectious Diseases, Vol. 8, Núm. 6

  2. Co-infections and superinfections complicating COVID-19 in cancer patients: A multicentre, international study

    Journal of Infection, Vol. 83, Núm. 3, pp. 306-313

  3. Daptomycin Plus Fosfomycin Versus Daptomycin Alone for Methicillin-resistant Staphylococcus aureus Bacteremia and Endocarditis: A Randomized Clinical Trial

    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, Vol. 72, Núm. 9, pp. 1517-1525

  4. Identification and validation of clinical phenotypes with prognostic implications in patients admitted to hospital with COVID-19: a multicentre cohort study

    The Lancet Infectious Diseases, Vol. 21, Núm. 6, pp. 783-792

  5. Multicentre, randomised, open-label, phase IV-III study to evaluate the efficacy of cloxacillin plus fosfomycin versus cloxacillin alone in adult patients with methicillin-susceptible Staphylococcus aureus bacteraemia: Study protocol for the SAFO trial

    BMJ Open, Vol. 11, Núm. 8

  6. Mural Endocarditis: The GAMES Registry Series and Review of the Literature

    Infectious Diseases and Therapy, Vol. 10, Núm. 4, pp. 2749-2764

  7. Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyperinflammatory state: a multicentre cohort study (SAM-COVID-19)

    Clinical Microbiology and Infection, Vol. 27, Núm. 2, pp. 244-252

2020

  1. An evidence-based bundle improves the quality of care and outcomes of patients with candidaemia

    Journal of Antimicrobial Chemotherapy, Vol. 75, Núm. 3, pp. 730-737

  2. Characteristics and predictors of death among 4035 consecutively hospitalized patients with COVID-19 in Spain

    Clinical Microbiology and Infection, Vol. 26, Núm. 11, pp. 1525-1536

2019

  1. Candidemia in solid organ transplant recipients in Spain: Epidemiological trends and determinants of outcome

    Transplant Infectious Disease, Vol. 21, Núm. 6

2016

  1. Caspofungin versus fluconazole as prophylaxis of invasive fungal infection in high-risk liver transplantation recipients: A propensity score analysis

    Liver Transplantation, Vol. 22, Núm. 4, pp. 427-435

2015

  1. A simple prediction score for estimating the risk of candidaemia caused by fluconazole non-susceptible strains

    Clinical Microbiology and Infection, Vol. 21, Núm. 7, pp. 684.e1-684.e9

  2. Influenza vaccination during the first 6 months after solid organ transplantation is efficacious and safe

    Clinical Microbiology and Infection, Vol. 21, Núm. 11, pp. 1040.e11-1040.e18